Syros Pharmaceuticals Inc.

NASDAQ:SYRS   3:58:49 PM EDT
5.58
-0.67 (-10.72%)
Products

Syros Receives FDA Orphan Drug Designation For SY-5609

Published: 09/13/2022 20:08 GMT
Syros Pharmaceuticals Inc. (SYRS) - Syros Receives FDA Orphan Drug Designation for Sy-5609 for the Treatment of Pancreatic Cancer.
Syros Pharmaceuticals Inc- Safety and Clinical Activity Data From Safety Lead-in Portion of Trial Are Expected in Second Half of 2022.
Syros Pharma - Under Clinical Supply Deal With Roche, Syros Supplying Sy-5609 for Combination Dosing Cohort in Roche's Phase 1/1b Intrinsic Trial.